glp-1 obesity drug news today september 29 2025 FDA takes aim at telehealth companies for promoting unofficial weight loss dupes It's outrageous how much we

Basics of meta-analysis: I2 is not an absolute measure of heterogeneity

Multi-compound aesthetics GLOW stack

Receptor Grade IGF-1 LR3 appears to provide almost three times as much cellular activation compared to similar IGF-1

The second concerns actin organisation, cell motility, adhesion and mechanisms related to endothelial cell migration

Multi-indication label expansion: Semaglutide approved across obesity, cardiovascular risk reduction, MASH, and sleep apnea creates a total addressable patient population of approximately 640 million globally nearly four times the obesity-only base adding new prescriber populations including cardiologists, hepatologists, and sleep medicine specialists